Search Results for “research” – Page 24 – media

Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding?

Jingtai Technology, which has the halo of being the “first AI pharmaceutical stock” in China, has attracted considerable attention in the secondary market. In the past few months, it has always sparked discussions within the industry due to occasional breakthroughs. According to Wind, on November 19th, Jingtai Technology’s lowest intraday price was HKD 3.51 per share, hitting a new low since its listing. The closing price for the day was HKD 4.00 per share, a drop of 12.66%. Compared to its issue price of HKD 5.28 per share, it has dropped 24.24%. In fact, since September this year, the stock price of Jingtai Technology has shown an overall fluctuating downward trend. According to the official website of Jingtai Technology, it is an innovative research and development platform company driven by artificial intelligence (AI) and robots. Based on technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale ...
- Source: drugdu
- 38
- November 21, 2024
Yangqi Medical Chip completes tens of millions of yuan in Pre-A round financing

According to the Medicine Intelligence Data Investment Pattern Database, Yangqi Medical Chip, committed to becoming a pioneer in precision nuclear medicine, recently announced the completion of tens of millions of yuan in PreA round financing. This round of financing is led by Anfeng Venture Capital, and the raised funds will mainly be used for market promotion of approved products, approval of new product research and development, and expansion of the pet radiotherapy market. Yangqi Medical Core was established in 2021, and its core founding team is composed of clinical experts in nuclear medicine, nuclear physics and artificial intelligence, tumor radiotherapy, and radiation physics from Stanford, Alibaba, and other domestic and foreign institutions. The company is headquartered in Shenzhen and has research and development centers in Hangzhou and Shanghai. It is reported that Yangqi Medical Core is deeply involved in the fields of nuclear medicine and tumor radiation therapy. In response ...
- Source: drugdu
- 37
- November 21, 2024
Endovascular stent approved through priority green channel

Recently, the Equipment Review Center of the National Medical Products Administration released the results of the priority approval application for medical devices (No. 14 of 2024), and Shanghai Qigong Medical Technology Co., Ltd. (hereinafter referred to as Qigong Medical)’s product – endovascular stent – passed the priority approval green channel. It is worth mentioning that this product is urgently needed in clinical practice and there are no registered medical devices of the same variety in China. Qigong Medical focuses on innovative vascular intervention products Against the backdrop of an aging population, the incidence of cardiovascular diseases in China continues to rise, with high mortality rates, difficult treatment, and high risks associated with aortic disease. At present, the clinical treatment options for aortic diseases in China mainly include surgical open treatment and endovascular intervention treatment. Endovascular intervention therapy is a rapidly developing clinical treatment technique in recent years, which combines a ...
- Source: drugdu
- 35
- November 21, 2024
Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified

On November 14, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Price of the Centralized Procurement of Amoxicillin and Other Drugs in the Guangdong Alliance” (hereinafter referred to as the “Notice”). It is worth noting that there are still 11 manufacturers and 20 specifications that refuse to reduce prices for rectification, including well-known pharmaceutical companies, including AstraZeneca, Sanofi, Eli Lilly and other foreign pharmaceutical companies, and their products include well-known brand drugs such as Plavix (clopidogrel bisulfate tablets), Iressa (gefitinib tablets), and Alimta (pemetrexed disodium for injection). The “Notice” emphasizes that the relevant drugs that refuse to accept the price rectification requirements will be disqualified from being selected and the selected price will be disqualified, and will be transferred to the alternative catalog. The platform will increase price risk warnings, and the task volume of the centralized ...
- Source: drugdu
- 35
- November 21, 2024
AstraZeneca’s new dual anti-cancer drug approved for clinical trials in China

On November 15, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that AstraZeneca’s Class 1 new drug AZD0486 was approved for two clinical trials with implicit approval, which are intended to be used for the treatment of previously untreated follicular lymphoma in adults; and relapsed and refractory follicular lymphoma in adults who have received at least 2 lines of systemic treatment or more. Public information shows that AZD0486 is a CD19/CD3-targeted bispecific T cell adaptor protein under development by AstraZeneca, which is a next-generation T cell adaptor. This is the first time that a drug has been approved for clinical trials in China for the indication of follicular lymphoma (FL). In a clinical study recently published by AstraZeneca, the product showed an overall response rate (ORR) of up to 96% when used to treat patients with relapsed/refractory FL (R/R FL). ...
- Source: drugdu
- 33
- November 21, 2024
【EXPERT Q&A】How to determine the clinical evaluation path of medical devices?

Drugdu.com expert’s response: The clinical evaluation pathway for medical devices is a crucial process for assessing their safety and effectiveness, determining their suitability for market release and clinical use. Below are the general steps and considerations for determining the clinical evaluation pathway for medical devices: Ⅰ. General Steps Clarify Product Characteristics and Scope of Application: Understand the basic principles, structural composition, manufacturing materials, and intended use of the medical device. First, confirm the scope of application of the product to facilitate targeted clinical evaluation. Assess Clinical Risks and Existing Clinical Data: Analyze potential adverse events or risks associated with the product during use. Evaluate whether sufficient clinical data exist to support the safety and effectiveness of the product. Select Clinical Evaluation Pathway: Based on product characteristics, clinical risks, and existing clinical data, select the most suitable clinical evaluation pathway. Ⅱ. Considerations Inclusion in the “Catalogue of Medical Devices Exempt from ...
- Source: drugdu
- 31
- November 20, 2024
Atropine that “does not adapt to local conditions”

Pharmaceutical companies around the world have high hopes for atropine. After all, the demand for myopia prevention is very clear and huge. The most critical thing is the extremely large demand group. According to Eyenovia’s estimates, myopia is estimated to affect about 25 million children in the United States, of which up to 5 million are considered to be at high risk of progressive myopia. The same is true in China. According to Guosheng Securities’ estimate, the size of the myopia group of children and young people aged 6-16 is about 78 million. For this group of people, there are currently two major problems: some groups have no effective means of delay, and those with means of delay need solutions with better compliance and lower costs. At present, among the main measures to control and delay myopia, wearing frame glasses is convenient but has poor effects; optical correction (wearing orthokeratology ...
- Source: drugdu
- 38
- November 20, 2024
Refusal to adjust prices, a number of pharmaceutical companies “out”

On November 18, at the 44th China Pharmaceutical Industry Development Summit Forum, Geng Hongwu, executive deputy director of the Medical and Health Research Center of the Tsinghua University Association of Senior Scientists, pointed out that the basic ideas of my country’s medical insurance drug price management at this stage mainly include: management scope, quality-price matching, reasonable price difference, medical insurance guidance, strict supervision, etc. “Exerting the effectiveness of drug price governance” is one of the key tasks of the National Medical Insurance Administration this year. That is, to promote special governance of online drug prices, explore new mechanisms for drug price formation, and increase the disclosure of price procurement credit evaluation. Recently, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Centralized Procurement Prices of Amoxicillin and Other Drugs of the Guangdong Alliance”. The relevant companies of 20 ...
- Source: drugdu
- 35
- November 20, 2024
Pumis announces equity acquisition agreement with BioNTech

According to the terms of the agreement, BioNTech will acquire 100% of Pumis’ issued share capital for a prepayment of $800 million (approximately RMB 5.781 billion) (subject to customary adjustment of the acquisition price), primarily in cash and a portion of American Depositary Shares (ADS). In addition, BioNTech will pay an additional milestone payment of up to $150 million (approximately RMB 1.084 billion) when Pumis meets the milestone conditions agreed upon by both parties. The transaction is expected to be completed in the first quarter of 2025, subject to customary delivery conditions and regulatory approvals. After the completion of this transaction, BioNTech will acquire full rights to the Pumis candidate drug pipeline and its bispecific antibody drug development platform, further expanding its business scope in China; Pumis Zhuhai will serve as the BioNTech China R&D center to conduct related R&D research; The Pumis Nantong production base, which meets international standards, ...
- Source: drugdu
- 44
- November 19, 2024
WuXi AppTec’s Couvet Site Receives EcoVadis 2024 Silver Medal Rating

Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its facility in Couvet, Switzerland, has received a silver medal in the 2024 business sustainability ratings by EcoVadis, a leading business sustainability rating provider. This recognition highlights WuXi AppTec’s steadfast commitment to integrating Environmental, Social, and Governance (ESG) priorities into its strategy and operations. EcoVadis provides benchmarks for rated companies in their industry to drive global supply chain sustainability and encourage industry-wide competence to achieve better global practice and continuous improvement. The ratings assess corporate performance across four core areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. With an impressive score, WuXi AppTec’s Couvet site ranks in the top 9% of all rated companies, showcasing its commitment to sustainable business practices. ...
- Source: drugdu
- 39
- November 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.